Virtual Library

Start Your Search

Ioannis Efstratiou

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-61 - EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer (ID 13174)

      12:00 - 13:30  |  Author(s): Ioannis Efstratiou

      • Abstract
      • Slides


      KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC); their prognostic role in advanced NSCLC is still under dispute. Given that ethnicity may play a role on mutational profiles of NSCLC, we report here on KRAS mutations in Greek NSCLC patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      KRAS and EGFR genotypes were evaluated in 424 NSCLC patients diagnosed from March 2000 to December 2012 and associated with clinicopathological parameters. Outcome comparisons were performed in 234 metastatic patients with available treatment data, following 1st line chemotherapy without tyrosine kinase inhibitors.

      4c3880bb027f159e801041b1021e88e8 Result

      KRAS mutations were found in 71 tumors of all histologies (22.2% in adenocarcinomas); most common types were p.G12C (39.5%), p.G12D (32%) and p.G12V (14%). EGFR mutations were found in 45 tumors (14.8% in adenocarcinomas; 72.6% of the classical type) and were mutually exclusive with KRAS mutations except for one case. At a median 3-year follow-up for all patients, KRAS status was a strong negative prognostic factor for overall survival (OS, p=0.0213) but not for progression-free survival (PFS), irrespective of mutation type. KRAS mutations conferred 64% increased risk of death in all 1st line treated patients and the worst OS compared to EGFR and any wild-type status in 1st line platinum-treated patients (p=0.0547). Rare EGFR mutations conferred significantly better outcome to platinum-treated patients (OS, p=0.0074; PFS, p=0.0338).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The presence of KRAS mutations seemed of adverse prognostic significance for survival, also in the presence of platinum-based 1st line treatment, while no prognostic differences were seen among different types of mutations.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.